| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Elutia Inc.: Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 | 2 | GlobeNewswire (USA) | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 14.10. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10. | Elutia appoints medical tech veteran Guido Neels to board of directors | 1 | Investing.com | ||
| 10.10. | Elutia beruft Medizintechnik-Veteranen Guido Neels in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 10.10. | Elutia Inc.: Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors | 2 | GlobeNewswire (USA) | ||
| 07.10. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Elutia closes $88M bioenvelope sale to Boston Scientific | 7 | MassDevice | ||
| 01.10. | Elutia Inc.: Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million | 8 | GlobeNewswire (USA) | ||
| 16.09. | Elutia Inc.: Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation | 1 | GlobeNewswire (USA) | ||
| 09.09. | Elutia To Sell EluPro And CanGaroo Bioenvelopes To Boston Scientific | 420 | AFX News | WASHINGTON (dpa-AFX) - Elutia Inc. (ELUT) has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes, designed to protect patients receiving implantable medical devices... ► Artikel lesen | |
| 09.09. | Elutia sells drug-eluting bioenvelope tech to Boston Scientific for $88M | 5 | MassDevice | ||
| 09.09. | ELUTIA INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.09. | Boston Scientific buys Elutia's bioenvelope business for $88 million | 5 | Seeking Alpha | ||
| 09.09. | Boston Scientific übernimmt Biohüllen-Produkte von Elutia für 88 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 09.09. | Elutia Inc.: Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million | 331 | GlobeNewswire (Europe) | - Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C.... ► Artikel lesen | |
| 15.08. | Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration | 1 | Seeking Alpha | ||
| 14.08. | Elutia Q2 2025 slides: EluPro drives growth amid cash concerns | 2 | Investing.com | ||
| 14.08. | Elutia Q2 2025: EluPro treibt Wachstum an, doch Liquidität gibt Anlass zur Sorge | 4 | Investing.com Deutsch | ||
| 14.08. | Elutia GAAP EPS of -$0.23, revenue of $6.3M | 1 | Seeking Alpha | ||
| 14.08. | ELUTIA INC. - 10-Q, Quarterly Report | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 6,972 | +1,54 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,170 | -0,52 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,900 | -2,21 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| NURIX THERAPEUTICS | 11,090 | +6,63 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 5,805 | -11,91 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,900 | +1,80 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| 89BIO | 14,785 | -0,10 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,340 | +13,40 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital |